ProBiotix Health #PBX – Publication of Circular and Notice of Requisitioned General Meeting

Further to the Company’s announcement on 25 September 2024, ProBiotix Health plc, the life sciences business developing probiotics to support cardiometabolic health, announces that today it will be publishing a circular to Shareholders (the “Circular”) containing details of a requisitioned general meeting of the Company (the “Requisitioned General Meeting”). The Requisitioned General Meeting will be […]

ProBiotix Health #PBX – New Commercial Partnership in Mexico

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a new commercial partnership with Mexico based raw materials and ingredients specialist Raff.  Founded in 1999, Raff is a distributor of raw materials and value-added ingredients, with a particular focus on the dairy and nutraceutical sectors. Backed by […]

ProBiotix Health #PBX – Q3 2024 Trading Update

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a Q3 2024 trading update (for the nine months to 30 September 2024) which shows ongoing strong momentum in the business.  Key highlights:  ·      Sales +39% to £1.525m (2023: £1.099m)   ·      Gross Profit +40% to £874k (2023: £623k) ·      Gross Profit margin stable at […]